Immune Checkpoint Therapeutics - Hot Targets & Pipeline Analysis
“IMMUNE CHECKPOINT THERAPEUTICS – HOT TARGETS & PIPELINE ANALYSIS” gives comprehensive insights on the various Immune Checkpoint modulators being developed for the treatment of various diseases. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins, Bi-specific Ab’s, Antibody drug conjugates, Cell therapy, Peptides, Oncolytic viruses and Vaccines. The report also covers hot targets in research for Checkpoint modulators.
This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Immune Checkpoints Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future Immune Checkpoint treatment space. The report in addition to the monotherapy covers the pipeline for combination therapies associated only with checkpoint agents.
In order to effectively deal various diseases, the immune system needs to be able to generate an appropriate counter response. However, as a part of the natural fail–safe mechanism, to limit overactive immune responses that could lead to an auto-immune disease, there are a number of markers (“immune checkpoint receptors”) found on both tumor cells and antigen presenting cells (dendritic cells, macrophages etc.) that can down-regulate or suppress T cells once the corresponding ligand is bound. Currently, Researchers are challenged to identify various avenues to prevent T cells from binding these tolerance-inducing ligands either through antibodies or recombinant forms of ligand or receptors. So, these T cells remain active and ready to tackle various diseases. Owing to its high response rate and prolonged overall patient survival the checkpoint therapeutics are gaining in popularity and have shown some impressive results in the areas of Oncology, Inflammation, Respiratory, Autoimmune and Infectious disease.
This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Immune Checkpoints Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future Immune Checkpoint treatment space. The report in addition to the monotherapy covers the pipeline for combination therapies associated only with checkpoint agents.
In order to effectively deal various diseases, the immune system needs to be able to generate an appropriate counter response. However, as a part of the natural fail–safe mechanism, to limit overactive immune responses that could lead to an auto-immune disease, there are a number of markers (“immune checkpoint receptors”) found on both tumor cells and antigen presenting cells (dendritic cells, macrophages etc.) that can down-regulate or suppress T cells once the corresponding ligand is bound. Currently, Researchers are challenged to identify various avenues to prevent T cells from binding these tolerance-inducing ligands either through antibodies or recombinant forms of ligand or receptors. So, these T cells remain active and ready to tackle various diseases. Owing to its high response rate and prolonged overall patient survival the checkpoint therapeutics are gaining in popularity and have shown some impressive results in the areas of Oncology, Inflammation, Respiratory, Autoimmune and Infectious disease.
REPORT DESCRIPTION INTRODUCTION
Emerging role of immunotherapy
Immune checkpoints
HOT TARGETS
Immune checkpoints-Types
Stimulatory checkpoint pathways
Inhibitory checkpoint pathways
Targets – Immune checkpoints Other immune checkpoint targets
Top companies based on revenue
Top companies based on Pipeline
MARKET SIZING & DEALS ANALYSIS
Market dynamics
Market sizing
Immune checkpoint Deals
PIPELINE ANALYSIS
Development stage
Leading players
Target analysis
Modalities
Therapeutic Segmentation
•Oncology immune checkpoint pipeline by indication
SMALL MOLECULES
Pipeline
Competitive landscape MONOCLONAL ANTIBODIES
Pipeline
Competitive landscape RECOMBINANT FUSION PROTEINS
Pipeline
Competitive landscape BISPECIFIC ANTIBODIES
Pipeline
Competitive landscape ANTIBODY DRUG CONJUGATES (ADC’s)
Pipeline
Competitive landscape
OTHERS
Pipeline
Competitive landscape
MAJOR PLAYERS
Company Profiles
Overview, Pipeline & Deals
Emerging role of immunotherapy
Immune checkpoints
HOT TARGETS
Immune checkpoints-Types
Stimulatory checkpoint pathways
Inhibitory checkpoint pathways
Targets – Immune checkpoints Other immune checkpoint targets
Top companies based on revenue
Top companies based on Pipeline
MARKET SIZING & DEALS ANALYSIS
Market dynamics
Market sizing
Immune checkpoint Deals
PIPELINE ANALYSIS
Development stage
Leading players
Target analysis
Modalities
Therapeutic Segmentation
•Oncology immune checkpoint pipeline by indication
SMALL MOLECULES
Pipeline
Competitive landscape MONOCLONAL ANTIBODIES
Pipeline
Competitive landscape RECOMBINANT FUSION PROTEINS
Pipeline
Competitive landscape BISPECIFIC ANTIBODIES
Pipeline
Competitive landscape ANTIBODY DRUG CONJUGATES (ADC’s)
Pipeline
Competitive landscape
OTHERS
Pipeline
Competitive landscape
MAJOR PLAYERS
Company Profiles
Overview, Pipeline & Deals
